IMBRIA
Dead / Abandoned — Abandoned — no statement of use filed (as of 01 Dec 2025)
What this means for you
This application is over — abandoned 01 Dec 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88193539
- Mark type
- Stylized text
- Filed
- 14 Nov 2018
- Published for opposition
- 28 Feb 2023
- Abandoned
- 01 Dec 2025
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for treatment of mitochondrial disorders, genetic diseases, neurological diseases, renal diseases, and blood diseases
Owner
- Imbria Pharmaceuticals, Inc., Boston, MA, US
- Imbria Pharmaceuticals, Inc., Boston, MA, US
Prosecution history
- 01 Dec 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 01 Dec 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 01 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 May 2025 — SOU EXTENSION 4 GRANTED
- 14 Apr 2025 — SOU EXTENSION 4 FILED
- 14 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Sept 2024 — SOU EXTENSION 3 GRANTED
- 04 Sept 2024 — SOU EXTENSION 3 FILED
- 04 Sept 2024 — SOU TEAS EXTENSION RECEIVED
- 23 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Apr 2024 — SOU EXTENSION 2 GRANTED
- 22 Apr 2024 — SOU EXTENSION 2 FILED
- 22 Apr 2024 — SOU TEAS EXTENSION RECEIVED
- 01 Dec 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED